All 2026 dates on sale. Register before December 31!
The World Health Organization’s endorsement of GLP-1 therapies for obesity treatment adds significant global validation to what providers already know: medical weight management continues to evolve with new clinical data, expanded treatment options, and refined care models. This update summarizes the four most clinically relevant developments shaping your practice and patient outcomes.
The FDA has approved the first oral GLP-1 pill for weight loss, delivering comparable efficacy to injectable formulations while addressing patient concerns about needles and cost. For aesthetic medicine practitioners, understanding this new GLP-1 treatment option is essential for informed patient conversations about weight management.
The WHO’s endorsement of GLP-1s for obesity marks a pivotal moment in medical weight management. Discover strategies to differentiate your practice and thrive in this evolving landscape.
The World Health Organization’s endorsement of GLP-1 therapies for obesity treatment adds significant global validation to what providers already know: medical weight management continues to evolve with new clinical data, expanded treatment options, and refined care models. This update summarizes the four most clinically relevant developments shaping your practice and patient outcomes.
Medicare GLP-1 price cuts are making headlines, but two separate programs create confusion for providers. Understanding the 2026 pilot program versus the 2027 price negotiation is essential for accurate patient counseling.
Adding GLP-1 weight loss to your practice is a rewarding way to help your patients and grow your revenue. This guide breaks down the process into four simple, actionable steps.
Discover the secret to building lasting patient trust in weight management by becoming an ally and a guide. This approach transforms the clinical relationship and drives better outcomes
On November 5, 2025, the FDA approved Restylane® Lyft for non-surgical chin augmentation, offering a new option for enhancing the lower face. This article explores the clinical data behind the approval, the principles of facial balancing, and critical patient safety considerations.
An estimated 22 million Americans using GLP-1 medications are now facing a new concern: loose skin on the body after rapid weight loss. This article evaluates Ultherapy PRIME’s recent FDA clearance for non-surgical body contouring, providing practitioners with evidence-based guidance on patient selection, combination therapies, and practice integration strategies.
October 2025 brought major regulatory and clinical updates shaping aesthetic medicine—from the FDA’s RF microneedling alert to new neurotoxin and device approvals. These developments highlight how evidence-based innovation and patient education are redefining safe, inclusive, and profitable practice growth.
Contains: Emerging trends, expert discussions, recommendations, technique comparisons… and more!